DNA · Ginkgo Bioworks Holdings, Inc.
Market Cap
$468.69M
Shares
67.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$170.16M
-25.1%
FY2025
Net Income
-$312.76M
+42.8%
FY2025
Operating Margin
-185.29%
+61.2pp
FY2025
Diluted EPS
-$5.64
+46.5%
FY2025
Operating Cash Flow
-$171.06M
+46.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $132.42M | $170.16MG | $227.04MG | $251.46MG | $477.71MG | $313.84M | $76.66M | $54.18M | |
| — | — | — | — | — | -$9.66M | $12.19M | -$48.24M | |
| $215.61M | $243.77M | $424.06M | $580.62M | $1.05B | $1.15B | $159.77M | $96.3M | |
| $30.78M | $183.29M | $246.16M | $385.03M | $1.43B | $862.95M | $38.31M | $29.48M | |
| $18.6M | $18.7M | $18M | $15.7M | $5.6M | $1.2M | $500K | $500K | |
| $54.03M | $58.99M | $63.02M | $70.51M | $42.55M | $29.08M | $13.86M | $10.76M | |
| — | $11.4M | $19.35M | — | — | — | — | — | |
| — | $485.43M | $786.8M | $1.12B | $2.69B | $2.14B | $213.68M | $125.78M | |
| -$306.07M | -$315.28M | -$559.76M | -$864.41M | -$2.21B | -$1.83B | -$137.03M | -$71.6M | |
| — | -185.29% | -246.54% | -343.76% | -462.41% | -582.62% | -178.75% | -132.14% | |
| -$252.03M | -$256.29M | -$496.74M | -$793.9M | -$2.17B | -$1.8B | -$123.16M | -$60.84M | |
| — | $0 | $94K | $93K | $106K | $2.37M | $2.39M | $2.42M | |
| -$4.17M | $1.68M | $12.25M | -$28.53M | $87.55M | -$9.66M | $12.19M | — | |
| — | $0 | $0 | -$2.64M | -$43.76M | -$77.28M | -$396K | -$27.53M | |
| -$11.72M | -$16.41M | -$28.83M | -$54.83M | -$53.34M | -$11.54M | -$3.73M | -$27.2M | |
| -$310.23M | -$313.6M | -$547.51M | -$892.94M | -$2.12B | -$1.84B | -$124.83M | -$119.84M | |
| -$594K | -$837K | -$479K | -$71K | -$15.03M | -$1.48M | $1.89M | $22K | |
| -$290.8M | -$312.76M | -$547.03M | -$892.87M | -$2.1B | -$1.83B | -$126.61M | -$119.33M | |
| — | -183.81% | -240.94% | -355.08% | -440.63% | -583.12% | -165.16% | -220.23% | |
| — | — | $0 | $0 | -$1.44M | -$6.6M | -$114K | -$530K | |
| -$291.51M | -$309.11M | -$550.32M | -$888.75M | -$2.11B | -$1.84B | -$126.72M | -$119.86M | |
| USD/shares | -$5.00 | -$5.64 | -$10.54 | -$18.37 | -$50.15 | -$54.00 | -$4.00 | -$4.00 |
| USD/shares | — | -$5.64 | -$10.54 | -$18.37 | -$50.20 | -$55.60 | -$4.00 | -$4.00 |
| shares | — | 55.46M | 51.89M | 48.61M | 41.98M | 34M | 31.87M | 28.73M |
| shares | — | 55.46M | 51.89M | 48.61M | 42M | 34.01M | 31.87M | 28.73M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.60×
EV/EBIT
—
Peer median 9.59×
P/E (TTM)
—
Peer median 12.62×
Peer medians compare against the 309 similar-size Biotechnology companies (of 508 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cell Engineering Segment | $132,746,000 | $173,972,000 | $143,531,000 | $143,666,000 | $112,989,000 |
| Biosecurity Segment | — | — | $107,924,000 | $334,040,000 | $200,848,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cell Engineering Revenue | $132,746,000 | $173,972,000 | $143,531,000 | $143,666,000 | $112,989,000 | — | — |
| Service | $37,409,000 | $53,071,000 | $78,975,000 | $298,585,000 | $177,808,000 | $8,729,000 | — |
| Product | $0 | $0 | $28,949,000 | $35,455,000 | $23,040,000 | $8,707,000 | — |
| Foundry Revenue | — | — | — | — | — | $59,221,000 | $54,184,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Biosecurity Segment | -$18,931,000 | -$30,619,000 | -$3,194,000 | $71,534,000 | $9,084,000 |
| Cell Engineering Segment | -$95,530,000 | -$218,567,000 | -$363,622,000 | -$249,180,000 | -$122,052,000 |
| Cell Engineering and Biosecurity Segments | -$114,461,000 | -$249,186,000 | -$366,816,000 | -$177,646,000 | — |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cell Engineering Segment | -72% | -125.6% | -253.3% | -173.4% | -108% |
| Biosecurity Segment | — | — | -3% | 21.4% | 4.5% |
Key facts
CIK
1830214
CUSIP
37611X209
13F (30d)
163 filings
151 filers
Visit website
Investor relations